Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene.

Familial hypercholesterolemia Genetic diagnosis Low-density lipoprotein cholesterol Low-density lipoprotein receptor Proprotein convertase subtilisin/kexin type 9

Journal

Journal of atherosclerosis and thrombosis
ISSN: 1880-3873
Titre abrégé: J Atheroscler Thromb
Pays: Japan
ID NLM: 9506298

Informations de publication

Date de publication:
01 Jun 2022
Historique:
pubmed: 2 7 2021
medline: 7 6 2022
entrez: 1 7 2021
Statut: ppublish

Résumé

The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria adopt a cut-off value of ≥ 9 mm of Achilles tendon thickness (ATT) detected by X-ray as one of the three key items. This threshold was determined based on an old data evaluating the ATT of 36 non-FH individuals that was published in 1977. Although the specificity of these clinical criteria is extremely high due to a strict threshold, there are a significant number of patients with FH whose ATT <9 mm. We aimed to determine a cut-off value of ATT detected by X-ray to differentiate FH and non-FH based on genetic diagnosis. The individuals (male/female=486/501) with full assessments of genetic analyses for FH-genes (LDLR and PCSK9), serum lipids, and ATT detected by X-ray at the Kanazawa University Hospital and National Cerebral and Cardiovascular Center Research Institute were included in this study. Receiver operating characteristic (ROC) analyses were conducted to determine a better cut-off value of ATT that predicts the pathogenic mutation of FH. The ROC analyses revealed that the best cut-off values of ATT are 7.6 mm for male and 7.0 mm for female, with the sensitivities/specificities of 0.83/0.83 for male and 0.86/0.85 for female, respectively. If the thresholds of ATT of 8.0/7.5 mm and 7.5/7.0 mm were applied to the diagnosis of male/female FH, the sensitivities/specificities predicting the pathogenic mutation of FH by the 2017 JAS FH clinical criteria would be 0.82/0.90 and 0.85/0.88, respectively. These results suggest that the cut-off value of ATT detected by X-ray is obviously lower than 9.0 mm, which was adopted by the 2017 JAS FH clinical criteria.

Identifiants

pubmed: 34193720
doi: 10.5551/jat.62869
pmc: PMC9174093
doi:

Substances chimiques

Receptors, LDL 0
PCSK9 protein, human EC 3.4.21.-
Proprotein Convertase 9 EC 3.4.21.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

816-824

Commentaires et corrections

Type : CommentIn

Références

Circulation. 2020 Jun 2;141(22):1742-1759
pubmed: 32468833
Circ Genom Precis Med. 2020 Aug;13(4):e000067
pubmed: 32698598
Atherosclerosis. 2001 Aug;157(2):514-8
pubmed: 11472754
J Atheroscler Thromb. 2010 Jul 30;17(7):667-74
pubmed: 20534948
N Engl J Med. 2019 Oct 17;381(16):1547-1556
pubmed: 31618540
J Am Coll Cardiol. 2018 Aug 7;72(6):662-680
pubmed: 30071997
J Clin Lipidol. 2021 Mar-Apr;15(2):358-365
pubmed: 33461934
J Clin Lipidol. 2020 May - Jun;14(3):346-351.e9
pubmed: 32331935
Pract Lab Med. 2020 Oct 19;22:e00180
pubmed: 33134466
Circulation. 2018 May 22;137(21):2218-2230
pubmed: 29581125
Circ J. 2017 Nov 24;81(12):1879-1885
pubmed: 28652530
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Eur Heart J. 2017 May 21;38(20):1573-1579
pubmed: 28159968
Atherosclerosis. 2019 Oct;289:101-108
pubmed: 31491741
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
J Atheroscler Thromb. 2018 Aug 1;25(8):751-770
pubmed: 29877295
Curr Opin Lipidol. 2017 Apr;28(2):120-129
pubmed: 28169869
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566
pubmed: 32439005
J Clin Lipidol. 2018 Nov - Dec;12(6):1436-1444
pubmed: 30241732
Atherosclerosis. 1977 Sep;28(1):61-8
pubmed: 911369
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2203-8
pubmed: 16123315
J Atheroscler Thromb. 2017 Mar 1;24(3):189-207
pubmed: 28179607
Atherosclerosis. 2018 Oct;277:234-255
pubmed: 30270054
Atherosclerosis. 2015 Jun;240(2):324-9
pubmed: 25875382

Auteurs

Hayato Tada (H)

Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences.

Mika Hori (M)

Department of Endocrinology, Research Institute of Environmental Medicine, Nagoya University.
Department of Endocrinology, Nagoya University Graduate School of Medicine.
Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

Kota Matsuki (K)

Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine.

Masatsune Ogura (M)

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

Atsushi Nohara (A)

Department of Genetics, Ishikawa Prefectural Central Hospital.

Masa-Aki Kawashiri (MA)

Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences.

Mariko Harada-Shiba (M)

Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH